NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyPhased Innovation Awards in AIDS Vaccine Research (R21/R33)
About This Grant
-Purpose. This program will support prophylactic vaccine research projects that are innovative, novel, may be high risk/high impact, and that exhibit the potential to advance AIDS prophylactic vaccine design or evaluation. All areas of investigation contributing to the development of an efficacious HIV/AIDS vaccine are welcome. Clinical trials will not be supported under this initiative. -Mechanism of Support. This FOA will utilize the NIH Phased Innovation (combined R21 [Phase I, Exploratory]/R33 [Phase II, Developmental]) grant mechanism. Awards will support milestone-driven exploratory/feasibility proof of concept studies (2 year R21 phase), with possible rapid transition to expanded development (2-3 year R33 phase). Initially funded R21 studies will be tested over two years via milestone completion, and eligible R21s will be further assessed for the R33 award. -Funds Available. Funding will be based on scientific and technical merit, program priorities, and availability of funds. The R21 award will be limited to $275,000 directs over the two year award period, and the R33 award will be limited to $300,000 in direct costs per annum. NIH anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.
Grant Summary
Phased Innovation Awards in AIDS Vaccine Research (R21/R33) is a National Institutes of Health grant providing funding that varies by award for municipality. Applications are accepted on a rolling basis. Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $0K
Rolling / Open
- 1Confirm your organization is eligible for Phased Innovation Awards in AIDS Vaccine Research (R21/R33) from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Phased Innovation Awards in AIDS Vaccine Research (R21/R33): Frequently Asked Questions
Who is eligible for the Phased Innovation Awards in AIDS Vaccine Research (R21/R33)?
Phased Innovation Awards in AIDS Vaccine Research (R21/R33) is offered by National Institutes of Health and is generally open to municipality. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Phased Innovation Awards in AIDS Vaccine Research (R21/R33) provide?
Phased Innovation Awards in AIDS Vaccine Research (R21/R33) provides an amount that varies by award per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Phased Innovation Awards in AIDS Vaccine Research (R21/R33) deadline?
Phased Innovation Awards in AIDS Vaccine Research (R21/R33) accepts applications on a rolling or ongoing basis, so there is no single fixed deadline. Confirm current timing with the funder, National Institutes of Health, before you apply, and submit as early as possible because rolling programs can close once funds are committed.
How do you apply for the Phased Innovation Awards in AIDS Vaccine Research (R21/R33)?
To apply for Phased Innovation Awards in AIDS Vaccine Research (R21/R33), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.